Abstract
CD8+ T lymphocytes mediate immunosurveillance against persistent virus infections and virus-induced neoplasia. Polyoma virus, a highly oncogenic natural mouse DNA virus, establishes persistent infection, but only a few mice are highly susceptible to tumors induced by the virus. Mature antiviral CD8+ T cells expand in tumor-susceptible mice, but their cytotoxic effector activity is nonfunctional in vivo. Here we show that the natural killer cell inhibitory receptor, CD94-NKG2A, is up-regulated by antiviral CD8+ T cells during acute polyoma infection and is responsible for down-regulating their antigen-specific cytotoxicity during both viral clearance and virus-induced oncogenesis.
Similar content being viewed by others
Main
Systemic viral infections drive the marked expansion and differentiation of antigen-specific CD8+ T cells, which have many antiviral cytotoxic and cytokine effector activities. With the eradication of infected cells, the population of antiviral CD8+ T cells contracts with a concomitant loss in antigen-specific cytotoxic activity; however, the rate of decline in ex vivo cytotoxic activity of antiviral CD8+ T cells on a per cell basis during viral clearance often exceeds the rate of reduction in cell number1,2,3. The dissociation between this effector activity and cell number points toward an important in vivo mechanism that mitigates potential bystander cytopathology as antiviral CD8+ T cells differentiate from effector to memory states. The premature activation of such an inhibitory process in virus-specific CD8+ T cells might lead to virus-induced cytopathology and the establishment of persistent viral infection.
The extent of T cell activation depends on the integration of positive signaling events initiated by the T cell receptor (TCR) and negative signals mediated by other T cell surface proteins4. Discrete subpopulations of antiviral CD8+ αβ T cells can express natural killer (NK) cell markers and receptors that impair the cytotoxic and cytokine activities of NK cells5. Inhibitory NK cell receptors (NKRs) fall into two main families of molecules: type I transmembrane proteins that belong to the immunoglobulin (Ig) superfamily, such as the human killer cell Ig-like receptors (KIRs) and leukocyte Ig-like receptors (LIRs); and type II transmembrane proteins that contain a C-type lectin domain, such as Ly49 homodimers in mice and CD94-NKG2A heterodimers in both mice and humans6.
Similar to TCRs, these inhibitory NKRs have major histocompatibility complex (MHC) class I molecules as ligands4. The Ig-like NKRs and Ly49 family interact with particular allelic variants of classical MHC class I molecules. In contrast, the ligand for the CD94-NKG2A receptor is the nonclassical MHC class I molecule HLA-E, or its murine ortholog Qa-1b, complexed to a nonapeptide, Qdm, which is derived from the leader sequence of particular classical MHC class I heavy chains7,8. Inhibitory NKRs possess intracytoplasmic immunoreceptor tyrosine inhibition motifs that, on tyrosine phosphorylation, recruit Src homology domain 2 (SH2)-containing protein tyrosine phosphatases, which are thought to dephosphorylate the immunoreceptor tyrosine activation motifs of NK cell–activating receptors9,10. Similar mechanisms might account for how inhibitory NKRs finely regulate the thresholds for TCR activation11.
Mounting evidence suggests that inhibitory NKRs regulate CD8+ T cell functionality. Because CD8+ T cells that express inhibitory KIR isoforms are oligoclonal populations found in the peripheral blood of normal individuals and exhibit a memory T cell phenotype, they are probably a result of antigen-specific expansion in vivo12. In HIV-infected individuals KIR+CD8+ T cells are detected at high frequencies, and in vitro–expanded HIV-specific CD8+ T cells exhibit KIR-dependent inhibition of antigen-specific effector activities13. Diminished CD8+ T cell–mediated antiviral and anti-tumor responses are seen in Ly49A-transgenic mice14,15; however, low expression of endogenous Ly49A only inhibits early events of TCR activation16. CD8+ T cells that infiltrate primary melanomas and metastatic lymph nodes express predominantly CD94-NKG2A17. An in vitro–expanded CD94-NKG2A+ subpopulation of melanoma-specific CD8+ T cells exhibits only weak cytotoxic activity that is amplified by blockade with CD94 monoclonal antibodies (mAbs)18. Taken together, these observations raise the possibility that CD8+ T cells that are chronically exposed to cognate antigen—derived from either tumors or persistent viral infections—are not anergic, but are functionally inhibited by NKR–MHC class I molecule interactions. However, there is no direct evidence that inhibitory receptors regulate antigen-specific CD8+ T cell function in vivo.
Infection by the highly oncogenic mouse polyoma virus induces a marked expansion of CD8+ T cells directed to an epitope derived from the viral middle T (MT) oncoprotein2. In mice that are susceptible to tumors induced by polyoma virus, this MT-specific CD8+ T cell response lacks antigen-specific cytotoxic effector activity; in contrast, tumor-resistant mice generate potent cytotoxicity against this epitope19. Because these dysfunctional CD8+ T cells are indistinguishable from antipolyoma cytotoxic lymphocyte (CTL) effectors in terms of intracellular concentrations of perforin and expression of T cell effector surface markers, and because they rapidly acquire antigen-specific cytotoxicity after in vitro restimulation, we proposed previously that their cytotoxic effector activity was restrained in vivo19. Here we show that the CD94-NKG2A receptor is induced in polyoma virus–specific CD8+ T cells during acute infection and is responsible for blocking their cytotoxic effector activity in mice susceptible to tumors induced by polyoma virus.
Results
Expression of CD94-NKG2 by antipolyoma CD8+ T cells
By day 6–9 of primary polyoma virus infection, adult C3H/HeN mice generate potent ex vivo cytotoxicity to the dominant H-2Dk–restricted polyoma virus epitope, amino acids 389–397 of the MT oncoprotein (MT(389–397)); this cytotoxicity coincides with a peak expansion of Dk-MT(389–397) tetramer+ CD8+ T cells2. With clearance of the infectious virus by day 13 of infection, MT(389–397)-specific ex vivo cytotoxicity falls sharply despite the presence of large numbers of antigen-specific CD8+ T cells2. Thus, we wanted to determine whether this apparent shut-off in the antiviral cytotoxic effector function of CD8+ T cells correlates with up-regulated expression of an inhibitory NKR during acute infection with polyoma virus.
At each timepoint after infection, less than 10% of Dk-MT(389–397) tetramer+ CD8+ T cells were stained by mAbs to either Dk-reactive Ly49 inhibitory molecules (Ly49A, Ly49C or Ly49I) or the DX5 NK cell surface marker (data not shown). In contrast, the proportion of MT(389–397)-specific CD8+ T cells that stained with either a mAb specific for the mouse NKG2A, NKG2C and NKG2E isoforms (Fig. 1) or a Qa-1b–Qdm tetramer (which binds specifically to heterodimers of CD94 and NKG2A, NKG2C or NKG2E20, data not shown) increased progressively through acute infection. By day 13, nearly 70% of the Dk-MT(389–397) tetramer+ CD8+ T cells expressed a CD94-NKG2 receptor. Of the three CD94-NKG2 receptors, only the CD94-NKG2A is inhibitory.
Few CD8+ T cells from naïve adult C3H/HeN mice expressed any of these NKRs (Fig. 1 and data not shown). Most of the memory MT(389–397)-specific CD8+ T cells expressed CD94-NKG2 with a mean fluorescence intensity equivalent to that expressed by NKG2+ Dk-MT(389–397) tetramer+ CD8+ T cells in acutely infected mice (Fig. 1 and data not shown); thus, once expressed, this inhibitory receptor was maintained stably by these antiviral CD8+ T cells. The NKG2 mAb also stained a population of Dk-MT(389–397) tetramer− CD8+ T cells, whose frequency increased coordinately with that of MT(389–397)-specific CD8+ T cells during the course of acute infection. These Dk-MT(389–397) tetramer− CD8+ T cells might recognize subdominant polyoma epitopes and/or arise through bystander activation, an effect that is thought to account for only a minor component of the overall virus-driven expansion of CD8+ T cells3. As seen typically for antigen-specific CD8+ T cells that express this and other NKR types5, all of the NKG2+CD8+ T cells that expanded during polyoma infection bore the CD11ahiCD44hi surface phenotype of antigen-experienced T cells (data not shown).
There was a strong association between the extinction of antigen-specific cytotoxicity and expression of the CD94-NKG2 receptor during acute polyoma virus infection (Fig. 2). We normalized the MT(389–397)-specific lytic activity at each timepoint after infection to the number of Dk-MT(389–397) tetramer+ CD8+ T cells, and compared it with the number of cells that costained with Qa-1b–Qdm tetramers. During days 6–9 of acute infection, when ex vivo MT(389–397)-specific cytotoxicity is maximal on the basis of the numbers of splenic mononuclear cells, the cytotoxic activity of MT(389–397)-specific CD8+ T cells plummets as virus is cleared2. The finding that expression of the CD94-NKG2 increased rapidly during this period implicates the CD94-NKG2A inhibitory receptor in restraining the cytopathic effector function of MT(389–397)-specific CD8+ T cells. Antiviral CD8+ T cells undergo a marked increase in functional avidity early in virus infection21, which raises the possibility that virus-specific CD8+ T cells may become progressively less sensitive to CD94-NKG2A–mediated inhibition over the course of acute infection; this might necessitate increased expression of this receptor late in infection to achieve functional inhibition.
Regulation of antipolyoma cytotoxicity by CD94-NKG2A
To determine directly whether the CD94-NKG2A receptor impaired the cytotoxicity of MT(389–397)-specific CD8+ T cells, we sorted Dk-MT(389–397) tetramer+ CD8+ T cells from day 8 infected mice into discrete subpopulations on the basis of CD94-NKG2 expression. We then analyzed them for their recognition of target cells pulsed with MT(389–397). The antigen-specific cytotoxic activity of MT(389–397)-specific CD8+ T cells matched their pattern of expression of the CD94-NKG2A receptor, with ex vivo antigen-specific killing only manifested by cells lacking surface CD94-NKG2A (Fig. 3).
We next determined whether interrupting the interaction between CD94-NKG2A and Qa-1b–Qdm could restore ex vivo polyoma-specific cytotoxic activity from acutely infected mice. Target cells pulsed with MT(389–397) were pretreated with mouse Qa-1b mAb and anti-mouse secondary antibody to provide maximal blocking and/or promote the internalization of surface Qa-1b molecules. We included brefeldin A to prevent re-expression of Qa-1b; brefeldin A also blocks de novo surface expression of other molecules that are potentially up-regulated by cross-linking Qa-1b (ref. 21). Compared with the progressive loss of MT(389–397)-specific killing of target cells pretreated with a control isotype-matched primary anti-Kk mAb (Fig. 4a), Qa-1b blockade restored MT(389–397)-specific cytotoxic activity. The capacity of Qa-1b blockade to restore this effector activity paralleled the proportion of MT(389–397)-specific CD8+ T cells that expressed CD94-NKG2A at different stages of acute infection (Fig. 4b). The 400:1 spleen cell to target cell ratio used for each of the three timepoints after infection corresponded to MT(389–397)-specific CD8+ T cell to target cell ratios of 3:1, 5:1 and 3:1, respectively. Qa-1b blockade failed to reveal MT(389–397)-specific ex vivo cytotoxicity in mice that are immune to polyoma virus (Fig. 4c), although the MT(389–397)-specific CD8+ T cell to target cell ratio was 3:1. This finding suggests that these immediate post-effector CD8+ T cells and memory CD8+ T cells represent functionally different stages of antigen-specific T cell differentiation.
We tested whether Qa-1b blockade could reveal ex vivo antigen-specific cytotoxicity by NKG2+ Dk-MT(389–397) tetramer+ CD8+ T cells sorted from the spleens of acutely infected adult mice. Target cells pulsed with MT(389–397) and pretreated with Qa-1b mAb but not Kk mAb markedly boosted target cell lysis by the NKG2+ population (Fig. 5a). Dk-MT(389–397) tetramer+ CD8+ T cells that lacked surface NKG2 expression exhibited strong ex vivo cytotoxicity regardless of Qa-1b blockade. In addition, mAb-mediated NKG2 blockade restored full antigen-specific cytotoxic activity to NKG2+ Dk-MT(389–397) tetramer+ CD8+ T cells (Fig. 5b). These studies support the conclusion that CD94-NKG2A receptors that are induced on antigen-specific CD8+ T cells during acute infection regulate cytotoxic effector function.
Antipolyoma CD8+ T cells in tumor-susceptible mice
Although MT(389–397)-specific CD8+ T cells expand during the neonatal infection of mice from H-2k strains that are resistant and susceptible to polyoma virus–induced tumors, ex vivo MT(389–397)-specific cytotoxicity is selectively absent in susceptible mice19. To investigate whether this effector function deficit is associated with expression of the CD94-NKG2A receptor, Dk-MT(389–397) tetramer+ CD8+ T cells from newborn-inoculated susceptible and resistant mice were costained with Qa-1b–Qdm tetramers. At day 13, when MT(389–397)-specific CD8+ T cell expansion is maximal19, approximately 40% of the Dk-MT(389–397) tetramer+ CD8+ T cells from mice of the resistant strain C3H/HeN failed to bind Qa-1b–Qdm tetramers. In contrast, nearly all of the MT(389–397)-specific CD8+ T cells in mice of the susceptible CBA/J strain bound Qa-1b–Qdm tetramers and therefore expressed CD94-NKG2 receptors (Fig. 6a). Dk-MT(389–397) tetramer+ CD8+ T cells from mice of either strain did not bind Qa-1b–Qdm.R5K tetramers, in which an arginine to lysine substitution in Qdm prevents binding to CD94-NKG2 receptors22.
We determined whether CD94-NKG2A receptors were responsible for negating ex vivo cytotoxic activity by MT(389–397)-specific CD8+ T cells in susceptible mice. Blockade and/or internalization of Qa-1b molecules from the surface of target cells pulsed with MT(389–397) restored potent ex vivo antigen-specific cytotoxicity in spleen cells from newborn-inoculated CBA/J mice at day 13 after infection (Fig. 6b). Thus, the CD94-NKG2A receptor clearly compromises the cytotoxic effector function of the dominant antipolyoma CD8+ T cell response in acutely infected mice that are susceptible to polyoma virus–induced tumorigenesis.
Memory antipolyoma CD8+ T cell responses
Polyoma virus infection induces efficient virus-neutralizing antibody responses in both resistant and susceptible mice23,24. Therefore, to investigate the impact of re-exposure to the MT(389–397) epitope on expansion and CD94-NKG2 expression by memory antipolyoma CD8+ T cells in resistant and susceptible mice, we infected newborn-inoculated, immune C3H/HeN and CBA/J mice with a recombinant vaccinia virus carrying a MT(389–397) minigene. This recombinant vaccinia virus, Vac.MT(389–397), efficiently expanded MT(389–397)-specific CTL effectors in adult-inoculated C3H/HeN and CBA/J mice (data not shown). Vac.MT(389–397) infection triggered a fivefold expansion of MT(389–397)-specific CD8+ T cells in immune C3H/HeN mice, whereas infection by a control recombinant vaccinia virus carrying a minigene for the H-2Kd–restricted GP(99–108) epitope of lymphocytic choriomeningitis virus (LCMV), Vac.GP(99–108), did not (Table 1); however, Vac.GP(99–108) infection elicited a threefold expansion in total splenic CD8+ cells as compared with unchallenged immune mice. The antigen-specific CD8+ T cell expansion in Vac.MT(389–397)-challenged immune C3H/HeN mice was accompanied by strong MT(389–397)-specific ex vivo cytotoxicity (data not shown). Nearly 60% of the Dk-MT(389–397) tetramer+ CD8+ T cells in these mice were found to express low amounts of CD94-NKG2 receptors (Fig. 7).
Immune susceptible CBA/J mice showed a different response to infection with Vac.MT(389–397), which failed either to induce expansion of MT(389–397)-specific CD8+ T cells or to alter their high expression of CD94-NKG2 (Table 1 and Fig. 7). As seen in immune C3H/HeN mice, however, vaccinia virus infection could induce expansion of splenic CD8+ T cells in immune CBA/J mice (Table 1). In contrast, in vitro restimulation of spleen cells from neonatally infected immune CBA/J mice led to a 30-fold expansion of Dk-MT(389–397) tetramer+ CD8+ T cells, of which 40% lacked expression of CD94-NKG2 (Fig. 7 and data not shown). As seen with in vitro restimulated spleen cells from 13-day infected CBA/J neonates19, in vitro expansion in immune CBA/J spleen cells generated potent MT(389–397)-specific cytotoxic activity (data not shown).
These findings suggest that a unique microenvironment is established in polyoma tumor–susceptible mice that not only restrains the cytotoxic effector function of antipolyoma CD8+ T cells during acute infection, but also blocks the expansion and differentiation of polyoma-specific memory CD8+ T cells.
Discussion
We have shown here that the CD94-NKG2A receptor down-regulated the antigen-specific cytotoxic effector function of antiviral CD8+ T cells during acute infection. The maximal expansion of antiviral CD8+ T cells responding to systemic infection tends to overshoot clearance of infectious virus2,3, probably because activation of individual naïve CD8+ T cells initiates a fixed, antigen-independent program of cell division and differentiation to CTL effectors25,26. As a result, mechanisms must be engaged to restrain T cell effector activity as numbers of infected cells become limiting. Inhibition of antiviral effector T cells is also essential to prevent widespread immunopathology against viruses that establish persistent infection, such as polyoma virus, while maintaining control over the extent of infection. We found that CD94-NKG2A expression is up-regulated by polyoma-specific CD8+ T cells in parallel with the resolution of virus infection and impairs their antigen-specific cytotoxicity before differentiation into memory T cells.
Regulation of CD94-NKG2A expression by polyoma-specific CD8+ T cells probably represents a primary determinant of host resistance to polyoma virus–induced tumors. Inherited susceptibility to polyoma virus–induced tumors results from the deletion of polyoma-specific CD8+ thymocytes that express TCR Vβ domains that react with the endogenous Mtv-7 superantigen27. As a consequence of this constrained antipolyoma CD8+ T cell repertoire, infectious polyoma virus attains high titers and is cleared at a substantially slower rate in susceptible than in resistant mice19. Because TCR activation up-regulates the expression of KIR in CD8+ T cells28, the rapid high-titer infection in polyoma tumor–susceptible mice might accelerate the expression of CD94-NKG2A by antiviral CD8+ T cells and prematurely terminate their cytotoxic effector capability. In connection with this, it should be noted that CD69, an early transient marker of TCR activation, was expressed in vivo by the MT(389–397)-specific CD8+ T cells that expressed the highest amounts of CD94-NKG2A (data not shown).
Alternatively, because specific cytokines such as interleukin 15 (IL-15), IL-10 and transforming growth factor-β can up-regulate the expression of CD94-NKG2A on CD8+ T cells in vitro29, and because virus infection can induce the production of IL-1530,31, the cytokine milieu in polyoma tumor–susceptible mice might also favor high stable expression of this inhibitory NKR. Functionally compromised antipolyoma CD8+ T cells at an early stage of acute infection would leave the host with a high residual viral burden. Because polyoma virus–induced cellular transformation is an infrequent event and tumorigenesis preferentially targets tissues carrying high numbers of replicating viral genomes32, a lack of CD8+ T cell–mediated control of persistent polyoma virus would promote tumor incidence. Conversely, efficient elimination of infected cells by antiviral CD8+ T cells during acute infection would limit the number of persistently infected cells, and in turn reduce the probability of viral oncogenesis.
Inhibitory NKRs may also impair the proliferation of antigen-specific CD8+ T cells. Constitutively high expression of Ly49A in transgenic mice limits both the virus-specific expansion of CD8+ T cells and effector function14. The murine KLRG1 inhibitory receptor is induced in antiviral CD8+ T cells and inhibits their antigen-specific proliferation33. Similarly, high expression of CD94-NKG2A by polyoma-specific CD8+ T cells in susceptible mice might present a barrier that fully blocks the ability of the MT(389–397) minigene recombinant vaccinia virus to drive their expansion. Because in vitro restimulation promoted efficient expansion of fully competent antipolyoma CTL effectors from immune susceptible mice, in vivo factors must account for the dysfunctional phenotype of these CD8+ T cells. Thus, strategies aimed at reducing the amount of persistent infection or neutralizing particular cytokines might impair negative regulation by CD94-NKG2A receptors and promote expansion of antigen-specific CTL secondary effectors.
Qa-1 has a broad tissue distribution, although its expression is generally lower than that of classical MHC class I molecules34. Interferon-γ (IFN-γ) up-regulates the expression of Qa-1b on pancreatic β cell lines35 and increases surface expression of functional Qa-1b molecules by the AG104A fibrosarcoma target cell line used here (J. M. Moser and L. Reed, unpublished data). As a dominant cytokine induced during viral infection, IFN-γ may similarly up-regulate expression of Qa-1 by antigen-presenting cells in infected tissues, and thereby promote signaling through CD94-NKG2 receptors expressed by NK cells and T cells. It has been shown that IFN-γ up-regulates expression of HLA-E and renders cells resistant to lysis mediated by NK cells36. Other cytokines, such as IFN-γ and IFN-β, which induce expression of classical MHC class I molecules37, may similarly up-regulate the expression of nonclassical MHC class I molecules. Although Qa-1b optimally binds Qdm, this nonclassical MHC class I molecule can be loaded with many different peptides22. The CD94-NKG2A receptor, however, is highly specific for Qa-1b–Qdm complexes22. This raises the possibility that the proportion of Qa-1b molecules occupied by Qdm may vary among cell types, or be altered by direct virus infection or the virus-induced cytokine microenvironment, and in turn affect the extent of CD94-NKG2A receptor activation.
Because polyoma virus is a persistent mouse pathogen24,38,39, antipolyoma CD8+ T cells must maintain surveillance against virus-induced neoplasia in tumor-resistant mice. Approximately 20% of the MT(389–397)-specific CD8+ T cells in resistant mice retain the CD94-NKG2A− phenotype in memory cells. Whether these T cells are capable of direct ex vivo cytotoxicity is difficult to ascertain given their small numbers in vivo; however, in vivo exposure of immune resistant mice to the MT(389–397) epitope presented via recombinant vaccinia virus infection led to the efficient expansion of MT(389–397)-specific CD8+ T cells that possessed strong antigen-specific ex vivo cytotoxicity, coupled with the emergence of a large CD94-NKG2A− subpopulation. Studies on other inhibitory NKRs suggest that these receptors may promote survival of memory CD8+ T cells, possibly by blocking activation-induced cell death40,41. By extension, CD94-NKG2A expression may be essential to maintain stable populations of polyoma-specific memory CD8+ T cells in the face of persistent antigen. We favor a linear differentiation pathway that involves conversion from CD94-NKG2A+ to CD94-NKG2A− memory CD8+ T cells, which subsequently differentiate into secondary effector CTLs. In this model, the small CD94-NKG2A− subpopulation of polyoma-specific memory CD8+ T cells in resistant mice represents a transition state for rapid differentiation into CTL effectors to eradicate cells that are persistently infected and/or transformed by polyoma virus.
Our study also points toward the existence of a distinct transient stage of antigen-specific CD8+ T cell differentiation that is interposed between effector CTL and memory stages. Interrupting the binding of CD94-NKG2A to its ligand, Qa-1b–Qdm, fully restored antigen-specific ex vivo cytotoxicity by polyoma-specific CD8+ T cells during acute infection, but failed to do so once these cells entered the memory stage. Thus, despite their phenotypic similarity, these post-CTL effectors are qualitatively different from memory CD8+ T cells in their potential for ex vivo cytotoxicity. Whether these "restrained" CTL effectors are a necessary precursor to memory differentiation is an important issue. Another possibility is that these CD8+ T cells may protect against an early resurgence of a primary or secondary virus infection, in which strong stimulation of the TCR might overwhelm CD94-NKG2A–mediated inhibition.
In summary, our results provide evidence for the functional inhibition of antiviral CD8+ T cells in vivo by an endogenous NKR. A general picture is emerging in which the magnitude and diversity of antigen-specific T cell effector activity are controlled by an integration of positive signals transduced by the TCR and negative signals originating from inhibitory cell surface molecules6,11. An imbalance in favor of inhibitory signaling may contribute to the dysfunction of antigen-specific CD8+ T cells in chronic viral infections and in tumor-bearing hosts42. Precise titration of antigen-specific cytotoxic effector activity by CD8+ T cells is likely to be critical for maintaining effective immunosurveillance, without immunopathologic consequences, against persistent virus infections.
Methods
Mice.
We purchased C3H/HeNCr and CBA/JCr mice from the Frederick Cancer Research and Development Center of the National Cancer Institute (Frederick, MD). Mice were housed and bred in accordance with the guidelines of the Institutional Animal Care and Use Committee, and the Department of Animal Resources at Emory University. We housed pregnant mice in individual microisolator cages and monitored them daily for births. Adult mice were used at 6–9 weeks.
Viruses.
The wild-type polyoma virus strain A2 was molecularly cloned and plaque purified, and virus stocks were prepared on primary baby mouse kidney cells as described43. We inoculated adult mice subcutaneously in their hind footpads with 2×106 plaque-forming units (PFU) of virus. Newborn mice were inoculated subcutaneously in their hind footpads with 2×105 PFU of virus within 12 h of birth. We made recombinant vaccinia viruses containing minigenes for the H-2Kd–restricted MT(389–397) polyoma CD8+ T cell epitope43 or the H-2Kd–restricted GP(99–108) LCMV epitope44 as described45,46. Adult mice were given an intraperitoneal inoculation of 5×105 PFU of virus.
51Cr-release assay.
We prepared 51Cr-labeled AG104A target cells (H-2k, MHC class II−, spontaneous fibrosarcoma47, maintained in Dulbeccos' modified Eagle's medium containing 5% fetal bovine serum (FBS)) as described43. For Qa-1b blocking experiments, 51Cr-labeled AG104A cells were pulsed with 10 μM peptide for 1 h at 37 °C in the presence of brefeldin A (10 μg/ml), and then incubated in the presence of brefeldin A (1 μg/ml) and FcBlock (BD Pharmingen, San Diego, CA) with mouse Qa-1b mAb (BD Pharmingen) or mouse H-2Kk mAb (Caltag, Burlingame, CA) at 20 μg/ml for 20 min at 22 °C in medium containing 1% serum, followed by goat anti-mouse antibody (20 μg/ml; Jackson ImmunoResearch, West Grove, PA) for 20 min at 22 °C in medium containing 1% serum. For NKG2 blocking experiments, untreated target cells or target cells treated with 10 μM MT(389–397) were cultured with Dk-MT(389–397) tetramer+ CD8+ T cells that had been sorted for NKG2 expression in the presence of mAb to mouse NKG2A, NKG2C and NKG2E (43 μg/ml, clone 20d5; BD Pharmingen) or an isotype-matched keyhole limpet hemocyanin (KLH) mAb (43 μg/ml, clone A110-2; BD Pharmingen). We resuspended target cells in Iscove's modified Dulbecco's medium (Life Technologies, Grand Island, NY) containing 10% FBS, and aliquoted 4,000 cells per well into V-bottom 96-well microtiter plates (Costar, Cambridge, MA). Spleen cells were treated with RBC lysing buffer (Sigma, St Louis, MO), and viable mononuclear cells were aliquoted at the indicated effector:target ratios into U-bottom 96-well microtiter plates (Costar) containing 5,000 target cells. After a 4–5 h incubation at 37 °C, half of the volume of each well was removed and counted in a Quantum γ-counter (Packard, Downers Grove, IL). We calculated the percentage of specific lysis as described43.
Flow cytometry.
Erythrocyte-lysed spleen cells were surface stained with fluorescein isothiocyanate (FITC), phycoerythrin (PE) or Tricolor-conjugated CD8α mAb (clone CT-CD8a; Caltag), and then FITC-conjugated mAb 20d5, CD11a mAb, or Ly-49A or Ly-49C/Ly-49I mAb (BD PharMingen), and PE-conjugated Qa-1b–Qdm tetramer, or allophycocyanin-conjugated Dk-MT(389–397) tetramer. We prepared H-2Dk tetramers of MT(389–397) and the Qa-1b tetramer containing either Qdm or the Qdm.R5K peptide, and verified their specificity as described22. Samples were acquired on a FACSCalibur (Becton-Dickinson, San Jose, CA).
For flow cytometry sorting, erythrocyte-lysed spleen cells were stained in phenol red–free RPMI 1640 medium (Life Technologies, Gaithersburg, MD) supplemented with 2% FBS, which contained allophycocyanin-conjugated Dk-MT(389–397) tetramer, FITC- or PE-conjugated anti-CD8α, and mAb 20d5 with PE-conjugated goat anti-mouse secondary antibody (Jackson ImmunoResearch) or PE-conjugated Qa-1b–Qdm tetramer. Cells were acquired and sorted on a FACSVantage (Becton Dickinson).
References
Bergmann, C. C., Altman, J. D., Hinton, D. & Stohlman, S. A. Inverted immunodominance and impaired cytolytic function of CD8+ T cells during viral persistence in the central nervous system. J. Immunol. 163, 3379–3387 (1999).
Lukacher, A. E., Moser, J. M., Hadley, A. & Altman, J. D. Visualization of polyoma virus-specific CD8+ T cells in vivo during infection and tumor rejection. J. Immunol. 163, 3369–3378 (1999).
Murali-Krishna, K. et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 8, 177–187 (1998).
Lanier, L. L. Face off–the interplay between activating and inhibitory immune receptors. Curr. Opin. Immunol. 13, 326–331 (2001).
McMahon, C. W. & Raulet, D. H. Expression and function of NK cell receptors in CD8+ T cells. Curr. Opin. Immunol. 13, 465–470 (2001).
Raulet, D. H., Vance, R. E. & McMahon, C. W. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19, 291–330 (2001).
Braud, V. M. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795–799 (1998).
Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E. & Raulet, D. H. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1b. J. Exp. Med. 188, 1841–1848 (1998).
Carretero, M. et al. Specific engagement of the CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib molecule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated NKG2-A: evidence for receptor function in heterologous transfectants. Eur. J. Immunol. 28, 1280–1291 (1998).
Le Drean, E. et al. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur. J. Immunol. 28, 264–276 (1998).
Ugolini, S. & Vivier, E. Regulation of T cell function by NK cell receptors for classical MHC class I molecules. Curr. Opin. Immunol. 12, 295–300 (2000).
Mingari, M. C. et al. Human CD8+ T lymphocyte subsets that express HLA class I-specific inhibitory receptors represent oligoclonally or monoclonally expanded cell populations. Proc. Natl Acad. Sci. USA 93, 12433–12438 (1996).
De Maria, A. et al. Expression of HLA class I-specific inhibitory natural killer cell receptors in HIV-specific cytolytic T lymphocytes: impairment of specific cytolytic functions. Proc. Natl Acad. Sci. USA 94, 10285–10288 (1997).
Zajac, A. J. et al. Impaired anti-viral T cell responses due to expression of the Ly49A inhibitory receptor. J. Immunol. 163, 5526–5534 (1999).
Brawand, P., Lemonnier, F. A., MacDonald, H. R., Cerottini, J. C. & Held, W. Transgenic expression of Ly49A on T cells impairs a specific antitumor response. J. Immunol. 165, 1871–1876 (2000).
Coles, M. C., McMahon, C. W., Takizawa, H. & Raulet, D. H. Memory CD8 T lymphocytes express inhibitory MHC-specific Ly49 receptors. Eur. J. Immunol. 30, 236–244 (2000).
Vetter, C. S. et al. Expression of CD94/NKG2 subtypes on tumor-infiltrating lymphocytes in primary and metastatic melanoma. J. Invest. Dermatol. 114, 941–947 (2000).
Speiser, D. E. et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med. 190, 775–782 (1999).
Moser, J. M., Altman, J. D. & Lukacher, A. E. Antiviral CD8+ T cell responses in neonatal mice: susceptibility to polyoma virus-induced tumors is associated with lack of cytotoxic function by viral antigen-specific T cells. J. Exp. Med. 193, 595–605 (2001).
Vance, R. E., Jamieson, A. M. & Raulet, D. H. Recognition of the class Ib molecule Qa-1b by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. J. Exp. Med. 190, 1801–1812 (1999).
Slifka, M. K. & Whitton, J. L. Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR. Nature Immunol. 2, 711–717 (2001).
Kraft, J. R. et al. Analysis of Qa-1b peptide binding specificity and the capacity of CD94/NKG2A to discriminate between Qa-1–peptide complexes. J. Exp. Med. 192, 613–624 (2000).
Lukacher, A. E., Freund, R., Carroll, J. P., Bronson, R. T. & Benjamin, T. L. PyvS: a dominantly acting gene in C3H/BiDa mice conferring susceptibility to tumor induction by polyoma virus. Virology 196, 241–248 (1993).
Drake III, D. R. & Lukacher, A. E. b2-microglobulin knockout mice are highly susceptible to polyoma virus tumorigenesis. Virology 252, 275–284 (1998).
Kaech, S. M. & Ahmed, R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naive cells. Nature Immunol. 2, 415–422 (2001).
Wong, P. & Pamer, E. G. Cutting edge: antigen-independent CD8 T cell proliferation. J. Immunol. 166, 5864–5868 (2001).
Lukacher, A. E. et al. Susceptibility to tumors induced by polyoma virus is conferred by an endogenous mouse mammary tumor virus superantigen. J. Exp. Med. 181, 1683–1692 (1995).
Huard, B. & Karlsson, L. KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement. Nature 403, 325–328 (2000).
Mingari, M. C., Moretta, A. & Moretta, L. Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses. Immunol. Today 19, 153–157 (1998).
Ahmad, A., Sharif-Askari, E., Fawaz, L. & Menezes, J. Innate immune response of the human host to exposure with herpes simplex virus type 1: in vitro control of the virus infection by enhanced natural killer activity via interleukin-15 induction. J. Virol. 74, 7196–7203 (2000).
Azimi, N., Tagaya, Y., Mariner, J. & Waldmann, T. A. Viral activation of interleukin-15 (IL-15): characterization of a virus- inducible element in the IL-15 promoter region. J. Virol. 74, 7338–7348 (2000).
Wirth, J. J., Martin, L. G. & Fluck, M. M. Oncogenesis of mammary glands, skin, and bones by polyomavirus correlates with viral persistence and prolonged genome replication potential. J. Virol. 71, 1072–1078 (1997).
Voehringer, D. et al. Viral infections induce abundant numbers of senescent CD8 T cells. J. Immunol. 167, 4838–4843 (2001).
Transy, C. et al. A low polymorphic mouse H-2 class I gene from the Tla complex is expressed in a broad variety of cell types. J. Exp. Med. 166, 341–361 (1987).
Chun, T. et al. Constitutive and regulated expression of the class IB molecule Qa-1 in pancreatic β cells. Immunology 94, 64–71 (1998).
Cerboni, C. et al. Synergistic effect of IFN-g and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur. J. Immunol. 31, 2926–2935 (2001).
Biron, C. A. Interferons α and β as immune regulators–a new look. Immunity 14, 661–664 (2001).
Gross, L. G. in Oncogenic Viruses, 3rd edn 737–828 (Pergamon, Oxford, 1983).
Freund, R., Sotkinov, A., Bronson, R. T. & Benjamin, T. L. Polyoma virus middle T is essential for virus replication and persistence as well as for tumor induction in mice. Virology 191, 716–723 (1992).
Roger, J., Chalifour, A., Lemieux, S. & Duplay, P. Ly49A inhibits TCR/CD3-induced apoptosis and IL-2 secretion. J. Immunol. 167, 6–10 (2001).
Ugolini, S. et al. Involvement of inhibitory NKRs in the survival of a subset of memory- phenotype CD8+ T cells. Nature Immunol. 2, 430–435 (2001).
Welsh, R. M. Assessing CD8 T cell number and dysfunction in the presence of antigen. J. Exp. Med. 193, F19–F22 (2001).
Lukacher, A. E. & Wilson, C. S. Resistance to polyoma virus-induced tumors correlates with CTL recognition of an immunodominant H-2Dk-restricted epitope in the middle T protein. J. Immunol. 160, 1724–1734 (1998).
van der Most, R. G. et al. Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J. Immunol. 157, 5543–5554 (1996).
Deng, Y., Yewdell, J. W., Eisenlohr, L. C. & Bennink, J. R. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol. 158, 1507–1515 (1997).
van der Most, R. G. et al. Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology 240, 158–167 (1998).
Ward, P. L., Koeppen, H., Hurteau, T. & Schreiber, H. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J. Exp. Med. 170, 217–232 (1989).
Acknowledgements
We thank J. Altman, J. Bennink and J. Yewdell for critical review of the manuscript; J. Lindsay Whitton for LCMV GP(99–108) recombinant vaccinia virus; J. Kraft and J. Miller for Qa-1b–Qdm and Qa-1b–Qdm.R5K tetramers; and R. Karaffa for help with FACS. Supported by a grant from the NIH (to A. E. L.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Moser, J., Gibbs, J., Jensen, P. et al. CD94-NKG2A receptors regulate antiviral CD8+ T cell responses. Nat Immunol 3, 189–195 (2002). https://doi.org/10.1038/ni757
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni757
This article is cited by
-
A molecular signature of lung-resident CD8+ T cells elicited by subunit vaccination
Scientific Reports (2022)
-
NKG2A and COVID-19: another brick in the wall
Cellular & Molecular Immunology (2020)
-
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Journal for ImmunoTherapy of Cancer (2019)
-
Evidence of functional Cd94 polymorphism in a free-living house mouse population
Immunogenetics (2019)
-
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Nature (2017)